SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.67 USD
-0.04 (-1.48%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $2.61 -0.06 (-2.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -42.19 | -18.74 | -17.14 | -0.01 | NA |
Depreciation/Amortization & Depletion | 3.75 | 3.29 | 1.65 | 0.00 | NA |
Net Change from Assets/Liabilities | 2.33 | -0.24 | 13.45 | 0.00 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 11.00 | -7.77 | 5.79 | 0.00 | NA |
Net Cash From Operating Activities | -25.12 | -23.46 | 3.76 | -0.01 | NA |
Property & Equipment | -0.15 | -2.09 | -10.94 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.15 | -2.09 | -10.94 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 67.16 | 7.76 | 0.01 | 0.03 | NA |
Issuance (Repayment) of Debt | -0.13 | -2.42 | -0.20 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | -0.26 | 1.24 | -0.02 | 0.15 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | -5.52 | 34.34 | -0.08 | NA |
Net Cash from Financing Activities | 66.77 | 1.05 | 34.12 | 0.09 | NA |
Effect of Exchange Rate Changes | 0.02 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 41.52 | -24.50 | 26.93 | 0.08 | NA |
Cash at Beginning of Period | 15.05 | 39.55 | 12.61 | 0.00 | NA |
Cash at End of Period | 56.57 | 15.05 | 39.55 | 0.08 | NA |
Diluted Net EPS | -7.64 | -4.30 | -6.30 | NA | NA |
Fiscal Year End for SAB Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -12.36 | -5.03 | -42.19 | -19.34 | -14.23 |
Depreciation/Amortization & Depletion | 2.87 | 1.90 | 3.75 | 2.80 | 1.82 |
Net Change from Assets/Liabilities | -2.51 | -2.77 | 2.33 | 2.75 | 4.25 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -6.47 | -4.85 | 11.00 | 2.11 | 1.67 |
Net Cash From Operating Activities | -18.47 | -10.75 | -25.12 | -11.67 | -6.50 |
Property & Equipment | -0.18 | -0.13 | -0.15 | -0.08 | -0.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -19.96 | -31.23 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -20.14 | -31.36 | -0.15 | -0.08 | -0.04 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.02 | 0.02 | 67.16 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | -0.06 | -0.03 | -0.13 | -0.10 | -0.06 |
Increase (Decrease) Short-Term Debt | -0.44 | -0.22 | -0.26 | -0.77 | -0.66 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.24 | -0.17 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.72 | -0.39 | 66.77 | -0.86 | -0.72 |
Effect of Exchange Rate Changes | 0.00 | -0.03 | 0.02 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -39.32 | -42.53 | 41.52 | -12.62 | -7.27 |
Cash at Beginning of Period | 56.57 | 56.57 | 15.05 | 15.05 | 15.05 |
Cash at End of Period | 17.24 | 14.03 | 56.57 | 2.43 | 7.77 |
Diluted Net EPS | -0.79 | -0.54 | -3.74 | -1.00 | -1.40 |